Utilisateur:Nolanmiton/Brouillon

Cette page est un brouillon appartenant à Nolanmiton

Conseils de rédaction

→ N'hésitez pas à publier sur le brouillon un texte inachevé et à le modifier autant que vous le souhaitez.
→ Pour enregistrer vos modifications au brouillon, il est nécessaire de cliquer sur le bouton bleu : « Publier les modifications ». Il n'y a pas d'enregistrement automatique.

Si votre but est de publier un nouvel article, votre brouillon doit respecter les points suivants :

Respectez le droit d'auteur en créant un texte spécialement pour Wikipédia en français (pas de copier-coller venu d'ailleurs).
Indiquez les éléments démontrant la notoriété du sujet (aide).
Liez chaque fait présenté à une source de qualité (quelles sources – comment les insérer).
Utilisez un ton neutre, qui ne soit ni orienté ni publicitaire (aide).
Veillez également à structurer votre article, de manière à ce qu'il soit conforme aux autres pages de l'encyclopédie (structurer – mettre en page).

→ Si ces points sont respectés, pour transformer votre brouillon en article, utilisez le bouton « publier le brouillon » en haut à droite. Votre brouillon sera alors transféré dans l'espace encyclopédique.

Founded in 1932, Septodont is a pharmaceutical and medical device company mainly dedicated to developing, manufacturing and distributing dental consumables for dental professionals around the world1. It is headquarted in Saint-Maur-des-Fossés (France).

Today Septodont is world leader of dental anesthesia, manufacturing 500 million cartridges of local anesthetic cartridges every year. The group counts 1,500 employees and operates in more than 150 countries through its affiliates and international distribution network. The group owns 4 R&D centers and 8 manufacturing facilities across the world.

History

Septodont was founded in 1932 by Annie & Nestor Schiller. In the 1950’s and 1960’s, under the leadership of Henri Schiller, Septodont showed significant development with the introduction of dental therapeutics that are still appreciated today around the world such as Endomethasone, Alveogyl or Detartrine. At that same time Septodont also started to focus on dental anesthesia being amongst the frontrunners introducing local anesthetics in single use cartridges. These dental cartridges remain today the standard used in dentistry worldwide. The dedication of the company on dental anesthesia was reinforced over the years, with the acquisition of a manufacturing site dedicated to dental needles in France in 1990. In 2000, Septodont introduced the first articaine-based anesthetic in the United States (Septocaine®). Since then, the presence of the company in North America has been constantly reinforced with the acquisition of an injectable anesthetic facility in 2001 in Canada (Cambridge, ON) and the creation of a manufacturing site for restorative solutions in Colorado. Over the years the Septodont Group also extended its local presence in other territories opening commercial affiliates in India (1998), China (2001), Brazil (2003) and in European countries (United Kingdom, Germany, Poland, Benelux, Italy and Spain). Beyond the focus on dental anesthesia, Septodont invested in Research and Development towards bioactive and biocompatible therapeutic solutions. This led to the introduction of products based on a patented biosilicate technology, Biodentine (2010 –dentin restoration) and BioRoot RCS (2015- Root canal sealer)

Recently the Septodont group acquired 2 companies in Brazil (TDV – 2014, restorative material) and DLA (2016, injectable anesthetics), one in Canada (Duoject – 2015, design for injection devices) and opened a new manufacturing unit for injectable anesthetics in its headquarter in Saint-Maur-des-Fossés in France (2016)

Beyond the dental field, through its subsidiary Novocol Healthcare2 (created in 2015), Septodont also offers partnership with pharmaceutical and medical device companies to utilize its specialize manufacturing capabilities.

Septodont remains today a 100% family owned business under the leadership of Olivier Schiller (CEO).4

Organization

Executive Leadership Team • Olivier Schiller – Chief Executive Officer (CEO) • Todd Beechey-Chief Financial Officer (CFO) • Kent Chiu –Chief Operating Officer (COO) • Sophie Ragot-Satgé- President EMEA & Chief Marketing Officer (CMO) • Paul Mondock- President of Americas • Laurent Artaud-Chief Scientific Officer (CSO) • Jérôme Darribère- Chief Strategy & Human Resources Officer (CSHRO)

Entities

The Group Septodont has been headquartered in Saint-Maur-des-Fossés in France since 1984. Currently 4 out of the 8 manufacturing facilities of Septodont are dedicated to the dental anesthesia procedure: o Manufacturing sites dedicated to pain management : France (2 sites), Canada, Brazil o Manufacturing sites dedicated to other therapeutics : France, Brazil, United States, India

Over the years Septodont has reinforced its local presence through its own subsidiaries or sales offices in USA, Canada, France, China, Brazil, Germany, UK, Benelux, Poland, Italy and Spain. In all other countries the company is present through its network of distributors

Product Portfolio Septodont offers today a wide range of dental consumables, such as dental anesthetics, dentin restoration systems, or therapeutics for endodontics, restoration or surgery amongst others. In 2015, Septodont’s Pain Management portfolio generated 80% of the group’s turnover with the major part of it being the dental anesthetics (500 million cartridges per year). Beyond injectable anesthetics, Septodont also offers topical anesthetics, anesthesia reversal agent, dental needles (one afiliate in France is dedicated to manufacturing dental needles), and injection devices.

Septodont developed the Active BioSilicate technology™15 , a patented technology that ensures high purity of calcium silicate . As of today, 2 products are based on this technology: a bioactive dentine substitute with indications both in the crown and in the root (BiodentineTM16) ,and 7, a mineral-based root canal sealer for endodontic procedures (BioRoot RCS1)

Septodont’s surgery line covers haemostatic products, periodontology solutions and bone-grafting material based on Beta-tricalcium phosphate (B-TCP) with brands such as R.T.R

Lien externes Site web : www.septodont.com

Notes and references

1. “Septodont Awarded for “Endurance and Transmission” by ASMEP-ETI” oralhealthgroup.com. March 27, 2014

2. Novocolhealthcare .“who we are –novocolhealthcare home” novocolhealthcare.com. 3. Septodont. “Heritage & expertise-septodontusa company” septodontusa.com. 4. “Major Gift from Septodont Creates Septodont Lecture Hall at NYU College of Dentistry”. oralhealthgroup.com. April 15, 2013 5. “Vital pulpectomy and root filling with N2 or Endomethasone”, International Endodontic Journal, Volume 20, Issue 4, pages 194–204, July 1987 6. “Plasma cells and their immunoglobulins in the normal and delayed healing of the extraction wound in man”. ncbi.nlm.nih.gov. Br J Oral Surg. 1980 Sep;18(2):100-6 7. “The Effect of Prophylactic Polishing Pastes on Surface Roughness of Indirect Restorative Materials”. ScientificWorldJournal. Mar 3 2014 9. “A Review on Biodentine, a Contemporary Dentine Replacement and Repair Material”. BioMed Research International,Volume 2014 (2014), Article ID 160951, 10 pages 10. “Novalar Announces Acquisition of OraVerse® by Septodont”. prnewswire.com. Mar 18, 2011 11. “Septodont to Acquire TDV”. oralhealthgroup.com. April 2, 2014 12. “Novocol Healthcare, a subsidiary of Septodont, acquires device company Duoject”. dentistryiq.com. October 26 2015 13. “Septodont acquires injectable dental anesthetic manufacturing plant from Dentsply International”. dentistryiq.com. February 1, 2016 14. Categories .“Product&MSDS ”. septodontusa.com 15. biodentine.“Categories -Product&MSDS ”. septodontusa.com 16. “Comparative Evaluation of Marginal Adaptation of BiodentineTM and Other Commonly Used Root End Filling Materials-An Invitro Study”. J Clin Diagn Res. 2014 Mar; 8(3): 243–245. 17. “Porosity and sealing ability of root fillings with gutta-percha and BioRoot RCS or AH Plus sealers. Evaluation by three ex vivo methods”. International Endodontic Journal, John Wiley & Sons Ltd. AUG 22 ,2015